Clinical Trials at Retina Northwest

Retina Northwest is committed to fostering cutting edge treatments for retinal diseases through our participation in clinical trials. Brief descriptions of our active clinical trials are listed below.  If you are a physician and have questions about any of our trials, or if you would like to refer a patient to our care, please contact our Clinical Research department at 503-274-2121.

Age-Related Macular Degeneration (AMD)

Atrophic (“Dry”)

 

APL2-303 (Dry AMD)
Principal Investigator: Colin Ma, MD
Study Coordinator: Ashley Adamo
Active, Currently Enrolling

Apellis: A Phase 3, multi-center, randomized, double masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with Geographic Atrophy secondary to Age Related Macular Degeneration.

Spiam (Dry AMD)
Principal Investigator: Michael Lee MD
Study Coordinator: Brian Puckett
Active, Currently Enrolling

A phase II, randomized, double-masked, placebo-controlled clinical study to evaluate the safety, efficacy, and pharmacokinetics of subcutaneous injections of Elamipretide in subjects with Age-Related Macular Degeneration with Geographic Atrophy.

Exudative (“Wet”)

 

GR40548 (Archway)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Enrollment Closed

Archway: A Phase 3, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.

 

 

Portal (Wet AMD)
Principal Investigator: Richard Dreyer MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Enrollment Closed

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with Neovascular Age-Related Macular Degeneration.

 

Tenaya (Wet AMD)
Principal Investigator: Apurva Patel MD
Study Coordinator: Ashley Adamo
Active, Currently Enrolling

A phase III, multicenter, randomized, double-masked, active comparator – controlled study to evaluate the efficacy and safety of Faricimab in patients with Neovascular Age-Related Macular Degeneration (Tenaya).

Diabetic Eye Diseases

Diabetic Retinopathy

 

Principal Investigator: Apurva Patel MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Currently Enrolling

Randomized Trial of Intravitreous Aflibercept vs. Intravitreous Bevacizumab plus Aflibercept for Treatment for Central-Involved Diabetic Macular Edema.

Principal Investigator: Paul Tlucek MD
Study Coordinator: Ashley Adamo
Active, Currently Enrolling

A Pilot Study evaluating Photobiomodulation Therapy for Diabetic Macular Edema (Protocol AE).

 

Principal Investigator: Mark Peters, MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Enrollment Closed

A Comparative Effectiveness Study of Intravitrela Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema Extension Study

Principal Investigator: Richard Dreyer, MD
Study Coordinator: Ashley Adamo
Active, Currently Enrolling

Phase 1b/2a study of OPT-302 in combination with aflibercept for Persistent Central-Involved Diabetic Macular Edema.

 

Principal Investigator: Paul Tlucek, MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Currently Enrolling

Yosemite: A Phase 3 multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema.

 

Vein Occlusions

SCORE LTF

SCORE LTF (Vein Occlusion)
Principal Investigator: Mark Peters MD
Study Coordinator: Ashley Adamo
Active, Enrollment Closed

Study of comparative treatments for Retinal Vein Occlusion 2: A multicenter, prospective, randomized non-inferiority trial of eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, comparing intravitreal Bevacizumab every 4 weeks with intravitreal Aflibercept every 4 weeks.

Macular Telangiectasia

 

Principal Investigator: Michael Lee, MD
Study Coordinator: Brian Puckett
Registry Only

A natural history observation and registry study of Macular Telangiectasia Type 2: The MacTel Study

Neurotech Macular Telangiecasia Surgical Study Phase 3

Principal Investigator: Michael Lee, MD
Study Coordinator: Brian Puckett
Active, Currently Enrolling

A phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus in Macular Telangiectasia Type 2.

Contrast
Zoom

A Decrease font size. A Reset font size. A Increase font size.